CNTO 5825

Drug Profile

CNTO 5825

Alternative Names: CNTO-5825; Human monoclonal antibody (CNTO 5825) - Centocor

Latest Information Update: 31 Mar 2016

Price : $50

At a glance

  • Originator Centocor Ortho Biotech
  • Developer Janssen Biotech
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Allergic asthma

Most Recent Events

  • 22 Jun 2011 Centocor Ortho Biotech is now called Janssen Biotech
  • 30 Sep 2010 Centocor completes a phase I trial in Allergic asthma in Belgium
  • 31 Jan 2010 Phase-I clinical trials in Allergic asthma in Belgium (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top